358 related articles for article (PubMed ID: 16490021)
1. The sensitivity of event logs, self-administered questionnaires and photoplethysmography to detect treatment-induced changes in female sexual arousal disorder (FSAD) diagnosis.
Rellini A; Meston C
J Sex Med; 2006 Mar; 3(2):283-91. PubMed ID: 16490021
[TBL] [Abstract][Full Text] [Related]
2. The sensitivity of continuous laboratory measures of physiological and subjective sexual arousal for diagnosing women with sexual arousal disorder.
Meston CM; Rellini AH; McCall K
J Sex Med; 2010 Feb; 7(2 Pt 2):938-50. PubMed ID: 20487501
[TBL] [Abstract][Full Text] [Related]
3. A phase 2a multicenter, double-blind, placebo-controlled, crossover trial to investigate the efficacy, safety, and toleration of CP-866,087 (a high-affinity mu-opioid receptor antagonist) in premenopausal women diagnosed with female sexual arousal disorder (FSAD).
Orri M; Abraham L; Giraldi A
J Sex Med; 2013 Oct; 10(10):2484-96. PubMed ID: 23347610
[TBL] [Abstract][Full Text] [Related]
4. FSFI scores of women with persistent genital arousal disorder compared with published scores of women with female sexual arousal disorder and healthy controls.
Leiblum SR; Seehuus M
J Sex Med; 2009 Feb; 6(2):469-73. PubMed ID: 19040625
[TBL] [Abstract][Full Text] [Related]
5. Opinion Paper: On the Diagnosis/Classification of Sexual Arousal Concerns in Women.
Althof SE; Meston CM; Perelman MA; Handy AB; Kilimnik CD; Stanton AM
J Sex Med; 2017 Nov; 14(11):1365-1371. PubMed ID: 28958593
[TBL] [Abstract][Full Text] [Related]
6. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores.
Wiegel M; Meston C; Rosen R
J Sex Marital Ther; 2005; 31(1):1-20. PubMed ID: 15841702
[TBL] [Abstract][Full Text] [Related]
7. Intended or unintended consequences? The likely implications of raising the bar for sexual dysfunction diagnosis in the proposed DSM-V revisions: 2. For women with loss of subjective sexual arousal.
Clayton AH; DeRogatis LR; Rosen RC; Pyke R
J Sex Med; 2012 Aug; 9(8):2040-6. PubMed ID: 23586432
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of alprostadil cream for the treatment of female sexual arousal disorder: a double-blind, placebo-controlled study in chinese population.
Liao Q; Zhang M; Geng L; Wang X; Song X; Xia P; Lu T; Lu M; Liu V
J Sex Med; 2008 Aug; 5(8):1923-31. PubMed ID: 18564348
[TBL] [Abstract][Full Text] [Related]
9. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.
Diamond LE; Earle DC; Heiman JR; Rosen RC; Perelman MA; Harning R
J Sex Med; 2006 Jul; 3(4):628-638. PubMed ID: 16839319
[TBL] [Abstract][Full Text] [Related]
10. Correlates of placebo response in the treatment of sexual dysfunction in women: a preliminary report.
Bradford A; Meston C
J Sex Med; 2007 Sep; 4(5):1345-51. PubMed ID: 17666035
[TBL] [Abstract][Full Text] [Related]
11. The Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS): psychometric properties within a Dutch population.
ter Kuile MM; Brauer M; Laan E
J Sex Marital Ther; 2006; 32(4):289-304. PubMed ID: 16709550
[TBL] [Abstract][Full Text] [Related]
12. Measuring women's satisfaction with treatment for sexual dysfunction: development and initial validation of the Women's Inventory of Treatment Satisfaction (WITS-9).
Corty EW; Althof SE; Wieder M
J Sex Med; 2011 Jan; 8(1):148-57. PubMed ID: 20722778
[TBL] [Abstract][Full Text] [Related]
13. The female sexual function index: a methodological critique and suggestions for improvement.
Meyer-Bahlburg HF; Dolezal C
J Sex Marital Ther; 2007; 33(3):217-24. PubMed ID: 17454519
[TBL] [Abstract][Full Text] [Related]
14. The effects of false positive and false negative physiological feedback on sexual arousal: a comparison of women with or without sexual arousal disorder.
McCall KM; Meston CM
Arch Sex Behav; 2007 Aug; 36(4):518-30. PubMed ID: 17333325
[TBL] [Abstract][Full Text] [Related]
15. Persistent genital arousal: disordered or normative aspect of female sexual response?
Leiblum S; Seehuus M; Brown C
J Sex Med; 2007 May; 4(3):680-689. PubMed ID: 17498105
[TBL] [Abstract][Full Text] [Related]
16. The impact of body awareness on sexual arousal in women with sexual dysfunction.
Seal BN; Meston CM
J Sex Med; 2007 Jul; 4(4 Pt 1):990-1000. PubMed ID: 17627744
[TBL] [Abstract][Full Text] [Related]
17. Toward personalized sexual medicine (part 2): testosterone combined with a PDE5 inhibitor increases sexual satisfaction in women with HSDD and FSAD, and a low sensitive system for sexual cues.
Poels S; Bloemers J; van Rooij K; Goldstein I; Gerritsen J; van Ham D; van Mameren F; Chivers M; Everaerd W; Koppeschaar H; Olivier B; Tuiten A
J Sex Med; 2013 Mar; 10(3):810-23. PubMed ID: 23130748
[TBL] [Abstract][Full Text] [Related]
18. Women's sexual function improves when partners are administered vardenafil for erectile dysfunction: a prospective, randomized, double-blind, placebo-controlled trial.
Goldstein I; Fisher WA; Sand M; Rosen RC; Mollen M; Brock G; Karlin G; Pommerville P; Bangerter K; Bandel TJ; Derogatis LR;
J Sex Med; 2005 Nov; 2(6):819-32. PubMed ID: 16422806
[TBL] [Abstract][Full Text] [Related]
19. Revised definitions of women's sexual dysfunction.
Basson R; Leiblum S; Brotto L; Derogatis L; Fourcroy J; Fugl-Meyer K; Graziottin A; Heiman JR; Laan E; Meston C; Schover L; van Lankveld J; Schultz WW
J Sex Med; 2004 Jul; 1(1):40-8. PubMed ID: 16422982
[TBL] [Abstract][Full Text] [Related]
20. Differentiating components of sexual well-being in women: are sexual satisfaction and sexual distress independent constructs?
Stephenson KR; Meston CM
J Sex Med; 2010 Jul; 7(7):2458-68. PubMed ID: 20456625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
